Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Nektar Therapeutics
In an interview, oncology development exec Peter Adamson reiterated the company’s view that THOR-707 is best-in-class, but more data are needed to see where its efficacy stands amid the IL-2 herd.
FDA grants emergency use authorization to OTC COVID-19 testing products as it targets allowing workplaces, schools and communities to access tools needed to screen for the virus rapidly and accurately.
The US agency has granted emergency use authorization to consumer COVID-19 testing products from Quidel, Abbott and BD.
Executives pointed to the IL-2 variant drug’s potential for subcutaneous administration as a key differentiator from other IL-2 variant programs.
- Drug Delivery
- Drug Discovery Tools
- Large Molecule
- Other Names / Subsidiaries
- Aerogen, Inc.
- Inhale Therapeutic Systems, Inc.
- Inheris Biopharma, Inc.
- Nektar Therapeutics (India) Private Limited